Results 61 to 70 of about 21,470 (167)

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

Nature Communications
A significant challenge for chimeric antigen receptor (CAR) T cell therapy against glioblastoma (GBM) is its immunosuppressive microenvironment, which is densely populated by protumoral glioma-associated microglia and macrophages (GAMs).
Tomás A. Martins, Deniz Kaymak, Nazanin Tatari, Fiona Gerster, Sabrina Hogan, Marie-Françoise Ritz, Valerio Sabatino, Ronja Wieboldt, Ewelina M. Bartoszek, Marta McDaid, Alexandra Gerber, Alicia Buck, Aisha Beshirova, Anja Heider, Tala Shekarian, Hayget Mohamed, Manina M. Etter, Philip Schmassmann, Ines Abel, Jean-Louis Boulay, Yasuyuki Saito, Luigi Mariani, Raphael Guzman, Berend Snijder, Tobias Weiss, Heinz Läubli, Gregor Hutter   +26 more
doaj   +1 more source

Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor macrophage (CAR-Mφ) therapy has promising therapeutic potential in solid tumors, yet challenges remain in target compatibility and systemic toxicity.Methods In this study, we screened the CD47-scFv sequence of CAR-Mφ ...
Min Liu, Xinyi Xu, Haotian Zhang, Anna He, Lili Lu, Fuyu Du, Meixi Jiang, Jingjing Qiu, Yuanhui Xu, Xiaocheng Gong, Xinruo Wang, Xianghan Zhang, Zhongliang Wang, Pengbo Ning   +13 more
doaj   +1 more source

Anticancer effects of anti-CD47 immunotherapy in vivo

OncoImmunology, 2019
The treatment of breast cancer largely depends on the utilization of immunogenic chemotherapeutics, which, as a common leitmotif, stimulate the exposure of calreticulin (CALR) on the surface of cancer cells, thereby facilitating their recognition by ...
Kristina Iribarren, Aitziber Buque, Laura Mondragon, Wei Xie, Sarah Lévesque, Jonathan Pol, Laurence Zitvogel, Oliver Kepp, Guido Kroemer   +8 more
doaj   +1 more source

Cell‐Based Micro/Nanorobots: From Living Carriers to Living Therapeutic Specialists

SmartBot, EarlyView.
Cell‐based micro/nanorobots integrate evolutionarily acquired biological intelligence with engineered capabilities, offering new opportunities for precision medicine in vivo. However, the complex physiological environments of different organs pose significant challenges to their clinical translation.
Junfeng Wu, Zhaoyu Zhang, Ke Xu, Enkuo Li, Yuting Cui, Yuting Zhou, Huanyu Zhou, Beipei Zhang, Shuai Jiang, Xiaodong Wang, Jialin Jiang, Lianqing Liu, Niandong Jiao   +12 more
wiley   +1 more source

Advances in research on layered double hydroxides for biomedical applications

Smart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang, Zhiping Zhang, Zhao Wang, Hao Zhang, Yen Leng Pak, Yingying Jing, Yurong Guo, Fang Li, Xiao Wang, Quanxiang Han, Lei Yu, Xuejiao Li, Xing Gao, Jibin Song   +13 more
wiley   +1 more source

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance

Journal for ImmunoTherapy of Cancer
Background Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. “Don‘t eat me” signals like CD47 allow tumors to evade macrophages and proliferate unchecked.
Chao Wang, Juan Zhang, Yi Luo, Yifei Wang, Weifeng Huang, Shaogang Peng, Andy Tsun, Xiaoniu Miao, Liandi Chen, Lidi Nan, Huayuan Liao, Ziyue Cui, Yanqing Lv, Xiaomu Wang   +13 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source